Related references
Note: Only part of the references are listed.The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders
Gin S. Malhi et al.
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY (2021)
Can antipsychotic medication administered for paediatric emotional and behavioural disorders lead to brain atrophy?
Tarun Bastiampillai et al.
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY (2019)
Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia
Jari Tiihonen et al.
JAMA PSYCHIATRY (2019)
Stopping and switching antipsychotic drugs
Nicholas Keks et al.
AUSTRALIAN PRESCRIBER (2019)
Implementing a clozapine supply service in Australian community pharmacies: barriers and facilitators
Bethany Wilson et al.
JOURNAL OF PHARMACEUTICAL POLICY AND PRACTICE (2019)
Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies
Taishiro Kishimoto et al.
SCHIZOPHRENIA BULLETIN (2018)
Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder
Mallik Greene et al.
JOURNAL OF MEDICAL ECONOMICS (2018)
Trends in and Predictors of Long-Term Antipsychotic Polypharmacy Use Among Ohio Medicaid Patients with Schizophrenia, 2008-2014
Cynthia A. Fontanella et al.
PSYCHIATRIC SERVICES (2018)
Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016
Fiona J. Charlson et al.
SCHIZOPHRENIA BULLETIN (2018)
Prescribing antipsychotics in older people: A mini-review
Sophie Behrrnan et al.
MATURITAS (2018)
Antipsychotic polypharmacy in the treatment of schizophrenia in China and Japan
Hong Qiu et al.
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY (2018)
Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017
Spencer L. G. James et al.
LANCET (2018)
Prevalence and correlates of antipsychotic polypharmacy in Hong Kong
Lung Stephanie Lock Man et al.
ASIAN JOURNAL OF PSYCHIATRY (2018)
International trends in antipsychotic use: A study in 16 countries, 2005-2014
Oskar Halfdanarson et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2017)
Prescribing trends and indications of antipsychotic medication in Hong Kong from 2004 to 2014: General and vulnerable patient groups
Kim S. J. Lao et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2017)
Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia
Georgia L. Stevens et al.
EARLY INTERVENTION IN PSYCHIATRY (2016)
Comparing the risk of tardive dyskinesia in older adults with first-generation and second-generation antipsychotics: a systematic review and meta-analysis
Angela O'Brien
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2016)
Antipsychotic prescribing and its correlates in New Zealand
Sangeeta Dey et al.
AUSTRALASIAN PSYCHIATRY (2016)
Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders
Cherrie Galletly et al.
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY (2016)
Barriers to the Use of Long-Acting Injectable Antipsychotics in the Management of Schizophrenia
Eduard Parellada et al.
CNS DRUGS (2016)
Antipsychotic medication in schizophrenia: a review
John Lally et al.
BRITISH MEDICAL BULLETIN (2015)
Off-Label Prescribing of Antipsychotics in Adults, Children and Elderly Individuals: A Systematic Review of Recent Prescription Trends
Louise Carton et al.
CURRENT PHARMACEUTICAL DESIGN (2015)
Prescribing of antipsychotics in UK primary care: a cohort study
Louise Marston et al.
BMJ OPEN (2014)
A Population-Based Study of Antipsychotic Prescription Trends in Children and Adolescents in British Columbia, From 1996 to 2011
Rebecca Ronsley et al.
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE (2013)
Antipsychotic Prescribing Pathways, Polypharmacy, and Clozapine Use in Treatment of Schizophrenia
Jessica L. Goeren et al.
PSYCHIATRIC SERVICES (2013)
Current approaches to treatments for schizophrenia spectrum disorders, part II: psychosocial interventions and patient-focused perspectives in psychiatric care
Wai Tong Chien et al.
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2013)
Patients' and clinicians' attitude towards long-acting depot antipsychotics in subjects with a first episode of psychosis
Matthias Kirschner et al.
THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY (2013)
Long-term Antipsychotic Treatment and Brain Volumes A Longitudinal Study of First-Episode Schizophrenia
Beng-Choon Ho et al.
ARCHIVES OF GENERAL PSYCHIATRY (2011)
Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology
Thomas R. E. Barnes
JOURNAL OF PSYCHOPHARMACOLOGY (2011)
Increasing off-label use of antipsychotic medications in the United States, 1995-2008
G. C. Alexander et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2011)
Personal and social functioning in schizophrenia: defining a clinically meaningful measure of maintenance in relapse prevention
Deborah Nicholl et al.
CURRENT MEDICAL RESEARCH AND OPINION (2010)
Real-world antipsychotic treatment practices
Troy A. Moore et al.
PSYCHIATRIC CLINICS OF NORTH AMERICA (2007)
Share Paper
